Guidelines for pathologic diagnosis of mesothelioma 2023 Update of the consensus statement from the International Mesothelioma Interest Group Guidelines


Authors: Husain, A. N.; Chapel, D. B.; Attanoos, R.; Beasley, M. B.; Brcic, L.; Butnor, K.; Chirieac, L. R.; Churg, A.; Dacic, S.; Galateau-Salle, F.; Hiroshima, K.; Hung, Y. P.; Klebe, S.; Krausz, T.; Khoor, A.; Litzky, L.; Marchevsky, A.; Nabeshima, K.; Nicholson, A. G.; Pavlisko, E. N.; Roden, A. C.; Roggli, V.; Sauter, J. L.; Schulte, J. J.; Sheaff, M.; Travis, W. D.; Tsao, M. S.; Walts, A. E.; Colby, T. V.
Title: Guidelines for pathologic diagnosis of mesothelioma 2023 Update of the consensus statement from the International Mesothelioma Interest Group
Abstract: center dot Context. - Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.-To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.-Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.-There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions. (Arch Pathol Lab Med. 2024;148:1251-1271; doi: 10.5858/ arpa.2023-0304-RA)
Keywords: mesothelioma; malignant pleural mesothelioma; sarcomatoid mesothelioma; renal-cell carcinoma; in-situ hybridization; differentiated papillary mesothelioma; epithelioid mesothelioma; peritoneal; alk rearrangements; p16 fish; bap1 immunohistochemistry
Journal Title: Archives of Pathology & Laboratory Medicine
Volume: 148
Issue: 11
ISSN: 0003-9985
Publisher: College of American Pathologists  
Date Published: 2024-11-01
Start Page: 1251
End Page: 1271
Language: English
ACCESSION: WOS:001347226600015
DOI: 10.5858/arpa.2023-0304-RA
PROVIDER: wos
PUBMED: 38586983
Notes: Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. William D Travis
    743 Travis
  2. Jennifer Lynn Sauter
    124 Sauter